Infrared Spectroscopy of Exprimate Urine and Blood for Prostate Cancer Detection

udwig-Maxilians-Universität München, Fakultät für Physik0 个研究点目标入组 750 人开始时间: 2021年5月26日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•All participants must fulfil all of the inclusion criteria and none of the exclusion criteria.
•1) Ability to consent to this study; participant has consented to participation in this study
•2) Willingness to fill in the study questionnaire
•3) Age = 50 years
•4) Belonging to one of the following three groups:
•o Random male patients with histopathologically proven prostate cancer (PCa), without any prior malignancy or cancer therapy within two years before study inclusion
•o Random male patients with benign prostate hyperplasia (BPH) and a negative digital-rectal examination of the prostate
•o Self-reported healthy and non-symptomatic patients (healthy controls”) without PCa or a BPH and with relevant blood and urine values within the normal range and a negative digital-rectal examination of the prostate

•1) Multiple cancers at present
•2) History of cancer or cancer therapy within the last two years before enrolment
•3) HIV, HCV, and HBV infections; acute infection
•4) Any condition preventing blood-draw or exprimate urine donation; incompletely filled plasma tube
•5) Any Vaccination (e.g. for SARS-CoV-2 or Influenza) within 14 days before study inclusion

发起方

udwig-Maxilians-Universität München, Fakultät für Physik